From Paralysis to Recovery: Antitoxin Treatment in Botulism

Botulism is an extremely rare diagnosis that some clinicians may never encounter during their careers. However, with recent cases of infant botulism associated with formula, it has become increasingly important for healthcare providers to understand its management. Botulism is a potentially fatal neuroparalytic illness resulting from exposure to the bacterium Clostridium botulinum. Effective treatment of this devastating disease requires early recognition, as healthcare facilities must contact their local or state health departments to facilitate procurement of botulism antitoxin from the Centers for Disease Control and Prevention (CDC). Heptavalent botulism antitoxin is currently the only antitoxin therapy available in the United States for adults and children older than 1 year, while Botulism Immune Globulin (BabyBIG) is used for infants younger than 1 year of age. The heptavalent antitoxin contains equine-derived antibodies to botulinum toxin types A through G, whereas BabyBIG provides antibodies to toxin types A and B. These antitoxins neutralize only unbound toxin; therefore, they can prevent progression of paralysis but cannot reverse established neuromuscular dysfunction, making early intervention critical. In this fast-paced IGNITE session titled “From Paralysis to Recovery: Antitoxin Treatment in Botulism,” attendees will gain practical clinical pearls and key takeaways, including: • A review of common causes of botulism and routes of exposure to Clostridium botulinum • A brief overview of clinical presentation in the emergency department and when clinicians should suspect botulism • Guidance on the antitoxin procurement process, including step-by-step instructions on contacting the CDC to ensure timely access • A comparison of heptavalent botulism antitoxin and BabyBIG, including toxin coverage and patient selection • Clinical considerations for dosing, preparation, and administration, as well as warnings, precautions, and safety considerations to evaluate prior to administration Attendees will leave with the knowledge and confidence to recognize and manage botulism in the rare—but potentially fatal—instances when it presents in the emergency department.